Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734591 · ClinicalTrials.gov registry record
Follow-Up Study for Exubera
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7,439
- Enrollment target
NCT00734591: Completed study, sponsored by Pfizer.
NCT00734591 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7,439 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734591 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7,439 participants
- Enrollment target
Study Summary
In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the expected range based on population-based data. There is currently not enough information to determine if any of the observed lung cancer cases were related to Exubera use, therefore, the study is being conducted to further investigate whether Exubera use makes the appearance of lung cancer more likely.
Primary Outcome
Reported deaths from primary lung cancer were adjudicated and classified into 4 categories: highly likely (clinical, radiographic, and/or histological data consistent with primary lung cancer); likely (some information may have been missing for definite diagnosis); unlikely; insufficient information. Highly likely and likely cases used to report rate and rate ratio of primary lung cancer mortality. Includes events from the start of the original trial to the end of FUSE.
Interventions
- DRUG Exubera
- OTHER Randomized diabetes therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,439 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
What the finished NCT00734591 record still lists
NCT00734591 is an observational study that tracks outcomes without assigning an intervention. Its 7,439 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Exubera is the first listed.
NCT00734591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734591 about?
NCT00734591 is a clinical study titled "Follow-Up Study for Exubera". In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines. All subjects diagnosed with lung cancer had a history of smoking and the number of lung cancer cases observed fell within the exp...
What is the current status of trial NCT00734591?
This trial is currently completed. The enrollment target is 7,439 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00734591?
The interventions under investigation include: Exubera (DRUG), Randomized diabetes therapy (OTHER).
Who is sponsoring clinical trial NCT00734591?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia